Corcept Therapeutics (NASDAQ:CORT) Reports Positive Phase 2 BELLA Ovarian Cancer Data

Aditi Sarkar

27 October 2026 12:25 AM AEDT

Corcept Therapeutics (NASDAQ:CORT) Reports Positive Phase 2 BELLA Ovarian Cancer Data

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Corcept reports median progression-free survival of 7.2 months in BELLA Part A.
The 95-patient study records an objective response rate of 59%.
Bevacizumab-naive patients show 8.1-month median progression-free survival.
The three-drug combination identifies no new safety signals.

Corcept Therapeutics Incorporated (NASDAQ:CORT) has announced positive results from Part A of its Phase 2 BELLA study evaluating Lifyorli, or relacorilant, alongside nab-paclitaxel and bevacizumab in women with platinum-resistant ovarian cancer. The open-label, single-arm study enrolled 95 patients and reported progression-free survival, response and early overall survival measurements.

Progression-Free Survival and Response Rates

Median investigator-assessed progression-free survival reached 7.2 months in BELLA Part A, and the objective response rate was 59%. For context, Corcept reported median progression-free survival of 5.4 months for Lifyorli plus nab-paclitaxel and 3.9 months for nab-paclitaxel alone in its separate pivotal Phase 3 ROSELLA trial. Corresponding ROSELLA response rates were 37% and 30%. These figures come from different studies, rather than a randomized comparison within BELLA.

Prior Bevacizumab Treatment Matters

Approximately half of BELLA participants had not previously received bevacizumab. In this subgroup, median progression-free survival was 8.1 months and the objective response rate was 66%. At six months, 91% were alive, compared with 88% of the overall BELLA population. Six-month overall survival in the separate ROSELLA groups was 82% for Lifyorli plus nab-paclitaxel and 77% for nab-paclitaxel alone. Median overall survival in BELLA had not been reached at primary analysis.

Safety and Current Treatment Status

The safety events were consistent with the known profiles of the individual medicines and the existing Lifyorli and nab-paclitaxel combination, with no new safety signals. Common events affecting at least one-quarter of patients included neutropenia, anemia, nausea, asthenia, nail disorders, peripheral neuropathy, fatigue and leukopenia. Lifyorli is approved in combination with nab-paclitaxel for specified adults with platinum-resistant ovarian, fallopian tube or primary peritoneal cancer, but it is not approved for use with bevacizumab.

Further Data and Development Plans

BELLA Part A enrolled patients at approximately 45 locations across North America, Europe and Asia-Pacific. Corcept plans to present the complete findings at a medical conference next year. It is also studying proprietary glucocorticoid receptor antagonists in several other cancers and combinations. The latest BELLA announcement establishes a new set of Phase 2 observations while further clinical development and regulatory considerations remain ahead.

FAQs

Q: How many patients joined BELLA Part A?

A: 95 women with platinum-resistant ovarian cancer.

Q: What was the response rate?

A: 59% across BELLA Part A.

Q: Is the three-drug combination approved?

A: No. Lifyorli is not approved in combination with bevacizumab.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.